Results 21 to 30 of about 14,435 (170)

Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection

Journal of Global Antimicrobial Resistance
Background: Nirmatrelvir-ritonavir is effective in the treatment of SARS-CoV-2 infection. It can cause drug‒drug interactions (DDIs), even several days after withdrawal, due to irreversible inhibition of the cytochrome enzyme.
Yun Han, Yonglan Gou, Jieqiong Liu, Lingyan Yu, Yuhua Zhao, Zhenwei Yu   +5 more
doaj   +2 more sources

Risk of acute liver injury following the nirmatrelvir/ritonavir use [PDF]

, 2023
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial.Aim: To quantify the risk and severity of acute liver injury (ALI ...
Lau, Kristy Tsz Kwan, Kristy Tsz Kwan Lau, Eric Ho Yin Lau, Benjamin J. Cowling, Leung, Gabriel M, Mak, Lung Yi, Lung Yi Mak, Au, Ivan Chi Ho, Yuen, Man Fung, Wing Yiu Cheng, Ivan Chi Ho Au, Ching Hei So, Wong, Carlos King Ho, So, Ching Hei, Cowling, Benjamin J, Carlos King Ho Wong, Gabriel M. Leung, Lau, Eric Ho Yin, Man Fung Yuen, Cheng, Wing Yiu   +19 more
core   +2 more sources

MOLNUPIRAVIR DAN NIRMATRELVIR/RITONAVIR SEBAGAI TERAPI ORAL COVID-19 [PDF]

, 2022
COVID-19 merupakan penyakit infeksi yang disebabkan virus SARS-CoV-2 yang dideklarasikan sebagai pandemik global pada tanggal 11 Maret 2020. COVID-19 dapat berakibat fatal hingga menyebabkan kematian, sehingga diperlukan penanganan yang serius. Obat-obat
Raharjo, Sofyan Budi, Angelina, Emanuela
core   +1 more source

NIRMATRELVIR/RITONAVIR (NIRI) EM PACIENTES COM COVID-19 E MALIGNIDADES HEMATOLÓGICAS: RELATO DO EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)

Brazilian Journal of Infectious Diseases, 2023
Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García, Francesco Marchesi, Livio Pagano, Oliver A. Cornely   +3 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

BMC Infectious Diseases
Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood.
Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +10 more
doaj   +2 more sources

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan, Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou, Shan Mou   +11 more
doaj   +1 more source

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

International Journal of Infectious Diseases, 2023
Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +12 more
doaj   +1 more source

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice

, 2023
Nirmatrelvir/ritonavir (Paxlovid) is indicated in patients who are at high risk of progressing to severe COVID-19. Many of these patients are concomitantly prescribed various medications for other indications. Ritonavir has no activity against SARS-CoV-2,
Magdalena Niedzielko, Dagmara Mirowska-Guzel, Rafał Kułakowski   +2 more
core   +1 more source

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

, 2023
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir
Jiménez-Lorenzo, M.-J., Varricchio, G., Delia, M., Di Blasi, R., Bergantim, R., Wolf, D., Tragiannidis, A., López-García, A., Papa, M.V., Salmanton-García, J., Guidetti, A., Samarkos, M., Ommen, H.-B., Garcia-Vidal, C., Mikulska, M., Glenthøj, A., Pagano, L., Dragonetti, G., Lahmer, T., Nunes Rodrigues, R., Gavriilaki, E., Fernández, N., Dávila-Valls, J., Nucci, M., García-Poutón, N., Ribera-Santa Susana, J.-M., Soto-Silva, A., Itri, F., Buquicchio, C., Finizio, O., Falces-Romero, I., Bonanni, M., Petzer, V., Marchesi, F., Piukovics, K., Eggerer, M., Pinczés, L.I., Yahya, A., Arellano, E., Serrano, L., Gräfe, S.K., De Jonge, N., Merelli, M., Nordlander, A., Méndez, G.-A., Zompi, S., Zambrotta, G.P.M., Van Praet, J., Biernat, M.M., Bilgin, Y.M., Cabirta, A., Espigado, I., Batinić, J., Del Principe, M.I., Busca, A., Jaksic, O., Cattaneo, C., Shan Kho, C., Meers, S., Hersby, D.S., Cornely, O.A., De Ramón, C., De Kort, E., Emarah, Z., Sili, U., Van Doesum, J., Verga, L., Criscuolo, M., Prattes, J., Cordini, G., Labrador, J., Aujayeb, A., Chi, L.Y.A., Marques de Almeida, J., Çolak, G.M., El-Ashwah, S., EPICOVIDEHA registry, Cordoba, R., Rahimli, L., Plantefeve, G., Coppola, N., Fianchi, L., Giordano, A., Jiménez, M., Dargenio, M., Prezioso, L., Stojanoski, Z., Martín-Pérez, S., Schönlein, M., Hernández-Rivas, J.-Á., Aiello, T.F., Blennow, O., Danion, F., Cuccaro, A., Ammatuna, E., González-López, T.J., Marchetti, M., Meletiadis, J., Machado, M., Hoenigl, M., Fracchiolla, N.S., Valković, T., Tascini, C., Anastasopoulou, A.N., Colović, N., Gomes da Silva, M., Vena, A., Duléry, R., Sacchi, M.V., Weinbergerová, B., Erben, N., Prin, R., Ormazabal-Vélez, I., Hassan, N., Besson, C., Farina, F., Stamouli, M.   +116 more
core   +3 more sources

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source